REVENUES

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

REVENUES

REVENUES

Disaggregation of Revenues

The following table summarizes our Total revenues:

	Three Months Ended March 31, 2024								Three Months Ended March 31, 2023
(in millions)	U.S.		Europe		Rest of World		Total		U.S.		Europe		Rest of World		Total
Product sales:
HIV
Biktarvy	$	2,315	$	365	$	265	$	2,946	$	2,161	$	304	$	212	$	2,677
Descovy	371		26		29		426		395		25		29		449
Genvoya	332		49		21		403		417		55		29		501
Odefsey	223		76		11		310		230		76		11		317
Symtuza - Revenue share(1)	104		33		3		141		98		36		4		138
Other HIV(2)	60		45		12		117		62		32		13		108
Total HIV	3,405		596		342		4,342		3,364		528		298		4,190
Liver Disease
Sofosbuvir/Velpatasvir(3)	248		79		78		405		204		90		90		385
Vemlidy	95		11		119		225		87		9		103		199
Other Liver Disease(4)	42		47		19		107		27		41		23		91
Total Liver Disease	385		137		215		737		318		140		217		675
Veklury	315		70		169		555		252		111		209		573
Oncology
Cell Therapy
Tecartus	55		36		8		100		59		27		3		89
Yescarta	170		158		52		380		210		121		28		359
Total Cell Therapy	225		195		60		480		269		148		31		448
Trodelvy	206		68		36		309		162		54		6		222
Total Oncology	431		262		96		789		431		202		37		670
Other
AmBisome	14		70		60		144		6		60		49		116
Other(5)	59		9		12		80		62		12		9		83
Total Other	73		79		71		224		69		72		58		199
Total product sales	4,609		1,144		894		6,647		4,434		1,053		819		6,306
Royalty, contract and other revenues	23		15		1		39		18		26		2		46
Total revenues	$	4,633	$	1,159	$	894	$	6,686	$	4,452	$	1,079	$	821	$	6,352

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2)    Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost.

(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.

(5)    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.

Revenues Recognized from Performance Obligations Satisfied in Prior Years

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

	Three Months Ended
	March 31,
(in millions)	2024		2023
Revenue share with Janssen and royalties for licenses of intellectual property	$	171	$	192
Changes in estimates	$	160	$	160

Contract Balances

The following table summarizes our contract balances:

(in millions)	March 31, 2024		December 31, 2023
Contract assets(1)	$	144	$	117
Contract liabilities(2)	$	84	$	109

________________________________

(1)    Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.

(2)    Generally results from receipt of advance payment before our performance under the contract.